Carlisle Companies Inc (CSL) 101.57 $CSL
Carlisle Companies to Announce 3rd Quarter Results on October 25, 2016
BusinessWire - Tue Sep 20, 7:59AM CDT
Carlisle Companies Incorporated (NYSE:CSL) will release third quarter 2016 results on Tuesday, October 25, 2016 after the market closes. A conference call to discuss the quarter's results will be held the same day at 5:00 p.m. Eastern. This conference call will be webcast live in a listen-only mode via Carlisle's website at www.carlisle.com. The replay of the webcast will be available on the Company's website shortly after the completion of the live call.
CSL: 101.57 (-1.13)
Carlisle Authorizes Repurchase of an Additional 4.1 Million Shares
BusinessWire - Tue Sep 13, 8:00AM CDT
The Board of Directors of Carlisle Companies Incorporated (NYSE:CSL) has authorized Carlisle to repurchase an additional 4.1 million shares, increasing Carlisle's authorization to approximately 5.0 million shares. The shares will be repurchased at management's direction from time to time in the open market at prevailing market prices, in privately negotiated transactions or through block trades. The timing and amount of repurchases will depend on the market price of Carlisle's common stock, general market conditions, applicable legal requirements and other corporate developments.
CSL: 101.57 (-1.13)
Carlisle Companies Elects Jonathan Collins to Board of Directors
BusinessWire - Tue Sep 13, 8:00AM CDT
Carlisle Companies Incorporated (NYSE:CSL) announced today that Jonathan Collins, Vice President and Head of eCommerce for Mylan N.V. (NASDAQ:MYL), has been elected to its Board of Directors, effective immediately. Mylan N.V. (Mylan) is a leading global pharmaceutical company, offering products to customers in 145 countries. Mylan's global headquarters are located in Canonsburg, PA, with 2015 net sales of $9.4 billion.
MYL: 42.06 (-0.53), CSL: 101.57 (-1.13)
Carlisle Cos Has Returned 25.9% Since SmarTrend Recommendation (CSL)
Comtex SmarTrend(R) - Fri Sep 09, 1:07AM CDT
SmarTrend identified an Uptrend for Carlisle Cos (NYSE:CSL) on February 1st, 2016 at $83.20. In approximately 7 months, Carlisle Cos has returned 25.88% as of today's recent price of $104.73.
CSL: 101.57 (-1.13)
Carlisle Cos Shares Up 25.5% Since SmarTrend's Buy Recommendation (CSL)
Comtex SmarTrend(R) - Thu Sep 01, 1:30PM CDT
SmarTrend identified an Uptrend for Carlisle Cos (NYSE:CSL) on February 1st, 2016 at $83.20. In approximately 7 months, Carlisle Cos has returned 25.48% as of today's recent price of $104.39.
CSL: 101.57 (-1.13)
FDA Accepts CSL Behring's Biologics License Application for First Subcutaneous Prophylactic Therapy to Prevent Hereditary Angioedema Attacks
PR Newswire - Tue Aug 30, 8:00AM CDT
CSL Behring announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the company's Biologics License Application (BLA) for its low-volume subcutaneous (SC) C1-Esterase Inhibitor (C1-INH) Human replacement therapy, CSL830, as prophylaxis to prevent Hereditary Angioedema (HAE) attacks. HAE is a rare genetic disorder caused by a deficiency of C1-INH, one of the proteins that work with the body's immune system to control inflammation. Symptoms of HAE include episodes of swelling in the face, abdomen, larynx and extremities and can be fatal if untreated.
CSL: 101.57 (-1.13)
Seqirus receives FDA approval for AFLURIA® QUADRIVALENT (Influenza Vaccine) for people 18 years of age and older
PR Newswire - Mon Aug 29, 8:31AM CDT
Seqirus announced today that the US Food and Drug Administration (FDA) has approved AFLURIA® QUADRIVALENT (Influenza Vaccine) for use in persons 18 years of age and older. AFLURIA QUADRIVALENT is an inactivated influenza vaccine indicated for active immunization against influenza disease caused by influenza A subtype viruses and type B viruses contained in the vaccine. Both AFLURIA QUADRIVALENT and AFLURIA® (Influenza Vaccine), are available in the US for the 2016-2017 influenza season.1
CSL: 101.57 (-1.13), NVS: 81.48 (-0.55)
Seqirus to highlight new data in seasonal influenza prevention at Options IX for the Control of Influenza conference
PR Newswire - Wed Aug 24, 3:37PM CDT
Seqirus announced today that seven poster presentations reporting results of the company's research and development in seasonal influenza prevention and control have been accepted at the Options IX for the Control of Influenza conference (Options IX) in Chicago, 24-28 August 2016.
CSL: 101.57 (-1.13), NVS: 81.48 (-0.55)
Seqirus Presents Integrated Analyses for Trivalent Adjuvanted Seasonal Influenza Vaccine for Young Children
PR Newswire - Wed Aug 24, 7:20AM CDT
Seqirus today announced results of two data integrated analyses from six randomized clinical trials evaluating the safety and immunogenicity of its trivalent MF59-adjuvanted seasonal influenza vaccine in children aged six months to less than six years.1,2 The two analyses were presented at the 28th International Congress of Pediatrics in Vancouver, Canada, 17-22 August 2016.
CSL: 101.57 (-1.13), NVS: 81.48 (-0.55)
Shares of CSL Up 25.8% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Wed Aug 17, 1:32PM CDT
SmarTrend identified an Uptrend for Carlisle Cos (NYSE:CSL) on February 1st, 2016 at $83.20. In approximately 7 months, Carlisle Cos has returned 25.82% as of today's recent price of $104.68.
CSL: 101.57 (-1.13)
Seqirus announces shipment of FLUAD(TM) (Influenza Vaccine, Adjuvanted) in the US for 2016-2017 flu season
PR Newswire - Tue Aug 16, 1:36PM CDT
Seqirus has begun shipping FLUAD(TM) (Influenza Vaccine, Adjuvanted) for the 2016-2017 flu season since gaining approval from the Food and Drug Administration (FDA) late November last year. FLUAD is the first and only adjuvanted seasonal influenza vaccine approved in the United States, and was specifically developed to help protect adults aged 65 and older from the flu.1
CSL: 101.57 (-1.13), NVS: 81.48 (-0.55)
Carlisle Companies Announces 17% Increase in Dividend and the 40th Consecutive Year of Dividend Increases
BusinessWire - Thu Aug 04, 11:19AM CDT
The Board of Directors of Carlisle Companies Incorporated (NYSE:CSL) has declared a 17% increase in the Company's regular quarterly dividend, to $0.35 per share from $0.30 per share. The dividend is payable on September 1, 2016 to shareholders of record at the close of business on August 18, 2016. This marks the 40th consecutive year of dividend increases for Carlisle shareholders.
CSL: 101.57 (-1.13)
Waste Connections (WCN) Beats on Q2 Earnings & Revenues
Zacks Equity Research - Zacks Investment Research - Thu Aug 04, 7:10AM CDT
Waste Connections Inc. (WCN) reported solid second-quarter 2016 results.
LUK: 18.84 (-0.23), WCN: 74.36 (-0.97), RSG: 50.78 (-0.43), CSL: 101.57 (-1.13)
Icahn Enterprises (IEP) Catches Eye: Stock Jumps 5.9%
Zacks Equity Research - Zacks Investment Research - Tue Aug 02, 7:40AM CDT
Icahn Enterprises, L.P. (IEP) saw its units rise almost 6% in the last trading session.
IEP: 50.34 (+0.48), CSL: 101.57 (-1.13)
Tyco (TYC) Beats Q3 Earnings Estimates, Withdraws Outlook
Zacks Equity Research - Zacks Investment Research - Fri Jul 29, 10:13AM CDT
Tyco International Ltd. (TYC) reported third-quarter fiscal 2016 results beating the Zacks Consensus Estimate by a penny.
LUK: 18.84 (-0.23), TYC: 45.59 (+0.58), ALLE: 68.67 (-0.38), CSL: 101.57 (-1.13)
Carlisle Companies to Announce 3rd Quarter Results on October 25, 2016
BusinessWire - Tue Sep 20, 7:59AM CDT
Carlisle Companies Incorporated (NYSE:CSL) will release third quarter 2016 results on Tuesday, October 25, 2016 after the market closes. A conference call to discuss the quarter's results will be held the same day at 5:00 p.m. Eastern. This conference call will be webcast live in a listen-only mode via Carlisle's website at www.carlisle.com. The replay of the webcast will be available on the Company's website shortly after the completion of the live call.
CSL: 101.57 (-1.13)
Carlisle Authorizes Repurchase of an Additional 4.1 Million Shares
BusinessWire - Tue Sep 13, 8:00AM CDT
The Board of Directors of Carlisle Companies Incorporated (NYSE:CSL) has authorized Carlisle to repurchase an additional 4.1 million shares, increasing Carlisle's authorization to approximately 5.0 million shares. The shares will be repurchased at management's direction from time to time in the open market at prevailing market prices, in privately negotiated transactions or through block trades. The timing and amount of repurchases will depend on the market price of Carlisle's common stock, general market conditions, applicable legal requirements and other corporate developments.
CSL: 101.57 (-1.13)
Carlisle Companies Elects Jonathan Collins to Board of Directors
BusinessWire - Tue Sep 13, 8:00AM CDT
Carlisle Companies Incorporated (NYSE:CSL) announced today that Jonathan Collins, Vice President and Head of eCommerce for Mylan N.V. (NASDAQ:MYL), has been elected to its Board of Directors, effective immediately. Mylan N.V. (Mylan) is a leading global pharmaceutical company, offering products to customers in 145 countries. Mylan's global headquarters are located in Canonsburg, PA, with 2015 net sales of $9.4 billion.
MYL: 42.06 (-0.53), CSL: 101.57 (-1.13)
Carlisle Cos Has Returned 25.9% Since SmarTrend Recommendation (CSL)
Comtex SmarTrend(R) - Fri Sep 09, 1:07AM CDT
SmarTrend identified an Uptrend for Carlisle Cos (NYSE:CSL) on February 1st, 2016 at $83.20. In approximately 7 months, Carlisle Cos has returned 25.88% as of today's recent price of $104.73.
CSL: 101.57 (-1.13)
Carlisle Cos Shares Up 25.5% Since SmarTrend's Buy Recommendation (CSL)
Comtex SmarTrend(R) - Thu Sep 01, 1:30PM CDT
SmarTrend identified an Uptrend for Carlisle Cos (NYSE:CSL) on February 1st, 2016 at $83.20. In approximately 7 months, Carlisle Cos has returned 25.48% as of today's recent price of $104.39.
CSL: 101.57 (-1.13)
FDA Accepts CSL Behring's Biologics License Application for First Subcutaneous Prophylactic Therapy to Prevent Hereditary Angioedema Attacks
PR Newswire - Tue Aug 30, 8:00AM CDT
CSL Behring announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the company's Biologics License Application (BLA) for its low-volume subcutaneous (SC) C1-Esterase Inhibitor (C1-INH) Human replacement therapy, CSL830, as prophylaxis to prevent Hereditary Angioedema (HAE) attacks. HAE is a rare genetic disorder caused by a deficiency of C1-INH, one of the proteins that work with the body's immune system to control inflammation. Symptoms of HAE include episodes of swelling in the face, abdomen, larynx and extremities and can be fatal if untreated.
CSL: 101.57 (-1.13)
Seqirus receives FDA approval for AFLURIA® QUADRIVALENT (Influenza Vaccine) for people 18 years of age and older
PR Newswire - Mon Aug 29, 8:31AM CDT
Seqirus announced today that the US Food and Drug Administration (FDA) has approved AFLURIA® QUADRIVALENT (Influenza Vaccine) for use in persons 18 years of age and older. AFLURIA QUADRIVALENT is an inactivated influenza vaccine indicated for active immunization against influenza disease caused by influenza A subtype viruses and type B viruses contained in the vaccine. Both AFLURIA QUADRIVALENT and AFLURIA® (Influenza Vaccine), are available in the US for the 2016-2017 influenza season.1
CSL: 101.57 (-1.13), NVS: 81.48 (-0.55)
Seqirus to highlight new data in seasonal influenza prevention at Options IX for the Control of Influenza conference
PR Newswire - Wed Aug 24, 3:37PM CDT
Seqirus announced today that seven poster presentations reporting results of the company's research and development in seasonal influenza prevention and control have been accepted at the Options IX for the Control of Influenza conference (Options IX) in Chicago, 24-28 August 2016.
CSL: 101.57 (-1.13), NVS: 81.48 (-0.55)
Seqirus Presents Integrated Analyses for Trivalent Adjuvanted Seasonal Influenza Vaccine for Young Children
PR Newswire - Wed Aug 24, 7:20AM CDT
Seqirus today announced results of two data integrated analyses from six randomized clinical trials evaluating the safety and immunogenicity of its trivalent MF59-adjuvanted seasonal influenza vaccine in children aged six months to less than six years.1,2 The two analyses were presented at the 28th International Congress of Pediatrics in Vancouver, Canada, 17-22 August 2016.
CSL: 101.57 (-1.13), NVS: 81.48 (-0.55)
Shares of CSL Up 25.8% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Wed Aug 17, 1:32PM CDT
SmarTrend identified an Uptrend for Carlisle Cos (NYSE:CSL) on February 1st, 2016 at $83.20. In approximately 7 months, Carlisle Cos has returned 25.82% as of today's recent price of $104.68.
CSL: 101.57 (-1.13)
Seqirus announces shipment of FLUAD(TM) (Influenza Vaccine, Adjuvanted) in the US for 2016-2017 flu season
PR Newswire - Tue Aug 16, 1:36PM CDT
Seqirus has begun shipping FLUAD(TM) (Influenza Vaccine, Adjuvanted) for the 2016-2017 flu season since gaining approval from the Food and Drug Administration (FDA) late November last year. FLUAD is the first and only adjuvanted seasonal influenza vaccine approved in the United States, and was specifically developed to help protect adults aged 65 and older from the flu.1
CSL: 101.57 (-1.13), NVS: 81.48 (-0.55)
Carlisle Companies Announces 17% Increase in Dividend and the 40th Consecutive Year of Dividend Increases
BusinessWire - Thu Aug 04, 11:19AM CDT
The Board of Directors of Carlisle Companies Incorporated (NYSE:CSL) has declared a 17% increase in the Company's regular quarterly dividend, to $0.35 per share from $0.30 per share. The dividend is payable on September 1, 2016 to shareholders of record at the close of business on August 18, 2016. This marks the 40th consecutive year of dividend increases for Carlisle shareholders.
CSL: 101.57 (-1.13)
Waste Connections (WCN) Beats on Q2 Earnings & Revenues
Zacks Equity Research - Zacks Investment Research - Thu Aug 04, 7:10AM CDT
Waste Connections Inc. (WCN) reported solid second-quarter 2016 results.
LUK: 18.84 (-0.23), WCN: 74.36 (-0.97), RSG: 50.78 (-0.43), CSL: 101.57 (-1.13)
Icahn Enterprises (IEP) Catches Eye: Stock Jumps 5.9%
Zacks Equity Research - Zacks Investment Research - Tue Aug 02, 7:40AM CDT
Icahn Enterprises, L.P. (IEP) saw its units rise almost 6% in the last trading session.
IEP: 50.34 (+0.48), CSL: 101.57 (-1.13)
Tyco (TYC) Beats Q3 Earnings Estimates, Withdraws Outlook
Zacks Equity Research - Zacks Investment Research - Fri Jul 29, 10:13AM CDT
Tyco International Ltd. (TYC) reported third-quarter fiscal 2016 results beating the Zacks Consensus Estimate by a penny.
LUK: 18.84 (-0.23), TYC: 45.59 (+0.58), ALLE: 68.67 (-0.38), CSL: 101.57 (-1.13)
